Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82,015 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. Among authors: li z, li w. J Hematol Oncol. 2022 Aug 18;15(1):113. doi: 10.1186/s13045-022-01334-z. J Hematol Oncol. 2022. PMID: 35982483 Free PMC article. Clinical Trial.
Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia.
Chen Y, Xu N, Yang Y, Liu Z, Xue M, Meng L, He Q, Chen C, Zeng Q, Zhu H, Du X, Zou J, He W, Guo J, Chen S, Yuan G, Wu H, Hong M, Cheng F, Liu B, Zhang Y, Li W. Chen Y, et al. Among authors: li w. Cancer Med. 2023 Aug;12(16):17239-17252. doi: 10.1002/cam4.6296. Epub 2023 Jul 6. Cancer Med. 2023. PMID: 37409506 Free PMC article.
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
Zhang X, Liu B, Huang J, Zhang Y, Xu N, Gale RP, Li W, Liu X, Zhu H, Pan L, Yang Y, Lin H, Du X, Liang R, Chen C, Wang X, Li G, Liu Z, Zhang Y, Liu Z, Hu J, Liu C, Li F, Yang W, Meng L, Han Y, Lin L, Zhao Z, Tu C, Zheng C, Bai Y, Zhou Z, Chen S, Qiu H, Yang L, Sun X, Sun H, Zhou L, Liu Z, Wang D, Guo J, Pang L, Zeng Q, Suo X, Zhang W, Zheng Y, Huang X, Jiang Q. Zhang X, et al. Among authors: li f, li w, li g. Blood. 2024 Oct 31;144(18):1951-1961. doi: 10.1182/blood.2024024761. Blood. 2024. PMID: 39046786 Free PMC article.
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. Among authors: li z, li w. J Hematol Oncol. 2022 Oct 31;15(1):159. doi: 10.1186/s13045-022-01369-2. J Hematol Oncol. 2022. PMID: 36316695 Free PMC article. No abstract available.
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. Among authors: li z, li w. J Hematol Oncol. 2023 Feb 20;16(1):13. doi: 10.1186/s13045-023-01414-8. J Hematol Oncol. 2023. PMID: 36803531 Free PMC article. Clinical Trial. No abstract available.
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, Liu X, Liang R, Chen C, Huang J, Zhu H, Pan L, Wang X, Li G, Liu Z, Zhang Y, Liu Z, Hu J, Liu C, Li F, Yang W, Meng L, Han Y, Lin L, Zhao Z, Tu C, Zheng C, Bai Y, Zhou Z, Chen S, Qiu H, Yang L, Sun X, Sun H, Zhou L, Liu Z, Wang D, Guo J, Pang L, Zeng Q, Suo X, Zhang W, Zheng Y, Zhang Y, Li W, Jiang Q. Zhang X, et al. Among authors: li f, li g, li w. Clin Lymphoma Myeloma Leuk. 2024 Jun;24(6):e257-e266. doi: 10.1016/j.clml.2024.02.008. Epub 2024 Feb 15. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38461040
82,015 results
You have reached the last available page of results. Please see the User Guide for more information.